Device Trial Radar · NCT04613544
Assess Safety, Efficacy and Usability of Application for Atrial Fibrillation Vocal Marker
Last checked: Nov 19, 2026Latest source record: Nov 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
400
Planned (sponsor's estimate)
Start
Apr 7, 2020
Primary completion
Aug 2021
Study completion Dec 2021
Sponsor
- Lead sponsor
- Cardiokol LtdNot on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 3, 2020
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Voice Assist Arrhythmia Monitoring (VAAM) is an application running on smartphones and/or landline phones that performs vocal tests for the monitoring of abnormalities in the heart rhythm.
Conditions
- Atrial Fibrillation
Interventions
Voice Assist Arrhythmia Monitoring (VAAM)Device
application flag the potential occurrence of irregular heart rhythms suggestive of atrial fibrillation (AF) and notify to further investigate the occurrence of the suspected AF episode by prompting user to initiate ECG test to confirm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety AssessmentTime frame: 6 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Meir Medical Center
Kfar Saba, Israel · Recruiting
Rabin Medical Center
Petah Tikva, Israel · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.